News Stocks MedPlus Health Services Subsidiary Faces 25-Day Drug License Suspension in MaharashtraMedPlus Health Services Subsidiary Faces 25-Day Drug License Suspension in Maharashtra
MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a 25-day drug license suspension order from Maharashtra's Food & Drug Administration for a store in Bhandara. The suspension, imposed under Rule 65 of Drugs and Cosmetics Act, 1940, carries a potential revenue loss of Rs 7.53 lacs. The company made this disclosure under SEBI listing regulations, with the order received on January 30, 2026.
*this image is generated using AI for illustrative purposes only.
MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received a drug license suspension order from Maharashtra's drug regulatory authority.
Regulatory Action Details
The suspension order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Bhandara, Maharashtra. The action targets a specific store location and carries significant operational implications for the subsidiary.
| Parameter: | Details |
|---|---|
| Affected Entity: | Optival Health Solutions Private Limited |
| Store Location: | Santaji Ward Warthi Road Bhandara, Maharashtra |
| Suspension Duration: | Twenty-five days |
| Order Receipt Date: | January 30, 2026 |
| Regulatory Authority: | Asst. Commissioner & Licensing Authority, Food & Drug Administration, Bhandara |
Legal Framework and Violations
The suspension has been imposed under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India. The specific nature of the violation or contravention that led to this action falls under these established pharmaceutical regulations.
Financial Impact Assessment
The company has quantified the potential financial implications of this regulatory action. The suspension is expected to result in a potential revenue loss of Rs 7.53 lacs for the affected store during the suspension period.
| Financial Impact: | Amount |
|---|---|
| Potential Revenue Loss: | Rs 7.53 lacs |
| Impact Duration: | Twenty-five days |
Regulatory Compliance and Disclosure
MedPlus Health Services has made this disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The disclosure falls under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has confirmed that complete details of this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. Company Secretary & Compliance Officer Manoj Kumar Srivastava signed the regulatory filing on January 31, 2026.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.44% | +1.27% | -1.45% | -12.31% | +10.15% | -28.74% |
20
